vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Turning Point Brands, Inc. (TPB). Click either name above to swap in a different company.

Turning Point Brands, Inc. is the larger business by last-quarter revenue ($121.0M vs $85.1M, roughly 1.4× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 6.8%, a 16.0% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 29.2%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $21.5M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 20.7%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Turning Point Australia (TPAUS) is a conservative lobby group based in Australia, affiliated with Turning Point USA but independent of it. Founded by Joel Jammal and first registered in 2023, the group has become active in trying to influence the outcome of the 2026 South Australian state election in March 2026.

FDMT vs TPB — Head-to-Head

Bigger by revenue
TPB
TPB
1.4× larger
TPB
$121.0M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508870.8% gap
FDMT
8508900.0%
29.2%
TPB
Higher net margin
FDMT
FDMT
16.0% more per $
FDMT
22.8%
6.8%
TPB
More free cash flow
FDMT
FDMT
$7.0M more FCF
FDMT
$28.5M
$21.5M
TPB
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
20.7%
TPB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FDMT
FDMT
TPB
TPB
Revenue
$85.1M
$121.0M
Net Profit
$19.4M
$8.2M
Gross Margin
55.9%
Operating Margin
17.3%
16.5%
Net Margin
22.8%
6.8%
Revenue YoY
8508900.0%
29.2%
Net Profit YoY
139.1%
239.8%
EPS (diluted)
$0.43
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
TPB
TPB
Q4 25
$85.1M
$121.0M
Q3 25
$90.0K
$119.0M
Q2 25
$15.0K
$116.6M
Q1 25
$14.0K
$106.4M
Q4 24
$1.0K
$93.7M
Q3 24
$3.0K
$90.7M
Q2 24
$5.0K
$93.2M
Q1 24
$28.0K
$83.1M
Net Profit
FDMT
FDMT
TPB
TPB
Q4 25
$19.4M
$8.2M
Q3 25
$-56.9M
$21.1M
Q2 25
$-54.7M
$14.5M
Q1 25
$-48.0M
$14.4M
Q4 24
$2.4M
Q3 24
$-43.8M
$12.4M
Q2 24
$-35.0M
$13.0M
Q1 24
$-32.4M
$12.0M
Gross Margin
FDMT
FDMT
TPB
TPB
Q4 25
55.9%
Q3 25
59.2%
Q2 25
57.1%
Q1 25
56.0%
Q4 24
56.0%
Q3 24
55.6%
Q2 24
54.1%
Q1 24
58.2%
Operating Margin
FDMT
FDMT
TPB
TPB
Q4 25
17.3%
16.5%
Q3 25
-67983.3%
21.8%
Q2 25
-396373.3%
22.6%
Q1 25
-383007.1%
21.8%
Q4 24
19.1%
Q3 24
-1704400.0%
22.9%
Q2 24
-849120.0%
24.5%
Q1 24
-136200.0%
23.2%
Net Margin
FDMT
FDMT
TPB
TPB
Q4 25
22.8%
6.8%
Q3 25
-63195.6%
17.7%
Q2 25
-364386.7%
12.4%
Q1 25
-342657.1%
13.5%
Q4 24
2.6%
Q3 24
-1461433.3%
13.6%
Q2 24
-699060.0%
14.0%
Q1 24
-115717.9%
14.5%
EPS (diluted)
FDMT
FDMT
TPB
TPB
Q4 25
$0.43
$0.40
Q3 25
$-1.01
$1.13
Q2 25
$-0.98
$0.79
Q1 25
$-0.86
$0.79
Q4 24
$0.15
Q3 24
$-0.79
$0.68
Q2 24
$-0.63
$0.68
Q1 24
$-0.66
$0.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
TPB
TPB
Cash + ST InvestmentsLiquidity on hand
$402.7M
$222.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$505.7M
$372.0M
Total Assets
$566.7M
$763.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
TPB
TPB
Q4 25
$402.7M
$222.8M
Q3 25
$305.1M
$201.2M
Q2 25
$293.2M
$109.9M
Q1 25
$321.4M
$99.6M
Q4 24
$424.9M
$48.9M
Q3 24
$501.9M
$33.6M
Q2 24
$541.9M
$142.2M
Q1 24
$525.9M
$130.9M
Stockholders' Equity
FDMT
FDMT
TPB
TPB
Q4 25
$505.7M
$372.0M
Q3 25
$369.0M
$358.2M
Q2 25
$420.9M
$224.8M
Q1 25
$469.7M
$203.4M
Q4 24
$510.6M
$190.4M
Q3 24
$552.9M
$185.7M
Q2 24
$588.3M
$172.8M
Q1 24
$600.6M
$160.0M
Total Assets
FDMT
FDMT
TPB
TPB
Q4 25
$566.7M
$763.8M
Q3 25
$424.0M
$742.8M
Q2 25
$473.6M
$595.8M
Q1 25
$515.7M
$564.6M
Q4 24
$560.4M
$493.4M
Q3 24
$604.0M
$488.0M
Q2 24
$620.1M
$591.6M
Q1 24
$629.9M
$586.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
TPB
TPB
Operating Cash FlowLast quarter
$28.6M
$24.9M
Free Cash FlowOCF − Capex
$28.5M
$21.5M
FCF MarginFCF / Revenue
33.5%
17.8%
Capex IntensityCapex / Revenue
0.1%
2.8%
Cash ConversionOCF / Net Profit
1.47×
3.03×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M
$43.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
TPB
TPB
Q4 25
$28.6M
$24.9M
Q3 25
$-46.5M
$3.3M
Q2 25
$-43.4M
$11.8M
Q1 25
$-47.8M
$17.4M
Q4 24
$-134.6M
$17.7M
Q3 24
$-29.4M
$13.2M
Q2 24
$-30.2M
$13.4M
Q1 24
$-29.1M
$22.6M
Free Cash Flow
FDMT
FDMT
TPB
TPB
Q4 25
$28.5M
$21.5M
Q3 25
$-46.6M
$-721.0K
Q2 25
$-43.4M
$7.8M
Q1 25
$-48.4M
$15.2M
Q4 24
$-138.4M
$16.6M
Q3 24
$-31.2M
$12.6M
Q2 24
$-30.6M
$10.9M
Q1 24
$-29.8M
$22.3M
FCF Margin
FDMT
FDMT
TPB
TPB
Q4 25
33.5%
17.8%
Q3 25
-51765.6%
-0.6%
Q2 25
-289620.0%
6.7%
Q1 25
-345635.7%
14.3%
Q4 24
-13837100.0%
17.8%
Q3 24
-1038966.7%
13.9%
Q2 24
-611840.0%
11.7%
Q1 24
-106421.4%
26.8%
Capex Intensity
FDMT
FDMT
TPB
TPB
Q4 25
0.1%
2.8%
Q3 25
101.1%
3.4%
Q2 25
440.0%
3.4%
Q1 25
4507.1%
2.1%
Q4 24
378600.0%
1.2%
Q3 24
59266.7%
0.7%
Q2 24
6980.0%
2.7%
Q1 24
2535.7%
0.4%
Cash Conversion
FDMT
FDMT
TPB
TPB
Q4 25
1.47×
3.03×
Q3 25
0.16×
Q2 25
0.82×
Q1 25
1.21×
Q4 24
7.34×
Q3 24
1.07×
Q2 24
1.03×
Q1 24
1.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FDMT
FDMT

Segment breakdown not available.

TPB
TPB

US$111.5M92%
Non Us$9.6M8%

Related Comparisons